ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2019
Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Measles - retrospective study of cases reported in a national notification system, Czech Republic, 2018-2024.BMC public health · 2026Article
- Patterns of Ocular Involvement and Associated Factors in Adult Measles: A Retrospective Study from a Romanian Tertiary Hospital.Clinics and practice · 2025Article
- Risk Analysis of Measles Outbreaks in Bulgaria and Romania for the Period 2000 to 2023: A Comparative Study.Journal of epidemiology and global health · 2025Article
- Ongoing measles outbreak in Romania: Clinical investigation and molecular epidemiology performed on whole genome sequences.PloS one · 2025Observational
- Time trend of measles burden on children and adolescents in BRICS-plus countries from 1990 to 2021 and prediction to 2032.Frontiers in microbiology · 2025Article
- Segmenting attitudes toward vaccination - behavioral insights into influenza vaccination refusal in Romania.Germs · 2024Article
- Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.Pathogens (Basel, Switzerland) · 2024Article
- Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy.Vaccines · 2024Article
- Suboptimal MMR Vaccination Coverages-A Constant Challenge for Measles Elimination in Romania.Vaccines · 2024Article
- Seroprevalence of Infections with TORCH Agents in Romania: A Systematic Review.Microorganisms · 2023Review
- Ongoing measles outbreaks in Romania, March 2023 to August 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- An interregional measles outbreak in Spain with nosocomial transmission, November 2017 to July 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Vaccination barriers and drivers in Romania: a focused ethnographic study.European journal of public health · 2023Article
- Subacute myoclonic measles encephalitis - An opportunistic HIV-associated infection.Frontiers in cellular neuroscience · 2023Article
- Evolving measles status and immunization policy development in six European countries.Human vaccines & immunotherapeutics · 2022Review
- Article
- Review of the measles epidemic in children from Central Eastern Europe in the third millennium.Experimental and therapeutic medicine · 2021Article
- A large outbreak of measles in the West Midlands, England, 2017-2018: descriptive epidemiology, control measures and lessons learnt.Epidemiology and infection · 2021Article
- Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.Immune network · 2021Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundSince January 2016, a resurgence of measles in Romania has led to the third measles epidemic in the past 12 years; 64 deaths have been confirmed so far-the highest number of measles-related deaths since the measles-mumps-rubella (MMR) vaccine was introduced in 2004.AimTo provide an overview on the characterisation on measles in Romania after the introduction of the MMR vaccine with focus on the current outbreak, laboratory and molecular analysis.MethodsWe performed an analysis of measles incidence and mortality after the introduction of MMR vaccination and a retrospective study using serological and molecular data in three consecutive outbreaks with focus on the current outbreak.ResultsIn the current outbreak, 17,533 measles cases were notified to the national surveillance system, 93% were unvaccinated. Measles virus was isolated from 429 samples and 283 were genotyped. Genotype B3 was predominant (n = 269) and sporadic measles cases associated with D8 genotype (n = 9) were also observed; genotype D4 and D8 were identified in the previous two measles outbreaks. The detection of several distinct measles virus B3 genotypes suggests multiple virus importations to Romania.ConclusionThe current outbreak is a consequence of insufficient vaccine coverage. Control measures were implemented to improve uptake of MMR vaccine, including administering the first MMR dose at a younger age (9-11 months) and offering catch-up vaccination to children that have not followed the recommended dosing schedule. More measures are needed to improve the surveillance performance and to achieve high routine MMR vaccination coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.